House De­moc­rats re­it­er­ate call for FDA to work on clin­i­cal di­ver­si­ty ac­tion plans

De­moc­rats on the House En­er­gy and Com­merce com­mit­tee on Tues­day sent a let­ter to FDA com­mis­sion­er Rob Califf re­quest­ing the agency give in­dus­try more guid­ance on mak­ing clin­i­cal tri­als more di­verse and in­clu­sive.

The guid­ance is tied to the Food and Drug Om­nibus Re­form Act of 2022 (FDO­RA), which re­quires phar­ma com­pa­nies to sub­mit di­ver­si­ty ac­tion plans to the FDA ahead of piv­otal tri­als. But the leg­is­la­tors say the agency has yet to com­ply with the law’s re­quire­ment that the FDA pub­lish draft guid­ance on the for­mat and con­tent of the plans no lat­er than Dec. 29, 2023.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER